Concord Biotech Limited has submitted a regulatory disclosure intimating about scheduled meetings between company officials and investors/analysts.
Meeting Details
- Date: 17th June 2026
- Time: 10:30 am onwards
- Nature of Meeting: 1x1 / Group Meeting
- Mode: Virtual
Discussion Parameters
The company explicitly states that discussions during these interactions will be based solely on publicly available information. The disclosure emphasizes that no unpublished price sensitive information (UPSI) is intended to be discussed during these meetings.
Contingency Note
The disclosure includes a note that changes to the schedule may occur due to exigencies on the part of either the participants or the company.
Company Representation
The disclosure is signed by Paritosh Trivedi, Company Secretary & Compliance Officer (ACS 63623), who serves as the designated compliance officer for the company.
Financial Impact
No specific financial impact is quantified in this disclosure. The meeting is informational in nature with no immediate financial implications disclosed.